2.75p+0.04 (+1.64%)24 Dec 2024, 12:24
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.AJ Bell logo
Jump to:

Shield Therapeutics PLC Fundamentals

Company NameShield Therapeutics PLCLast Updated2024-12-24
IndustryDrug Manufacturers - Specialty & GenericSectorHealthcare
Shares in Issue782.056 mMarket Cap£21.86 m
PE Ratio32.15Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-$0.05EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.4271Debt Equity Ratio36.3752
Asset Equity Ratio86.4344Cash Equity Ratio14.9704
Quick Ratio0.8856Current Ratio1.05
Price To Book Value50.0000ROCE0

Shield Therapeutics PLC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Shield Therapeutics PLC Company Financials

Assets202320222021
Tangible Assets$673,000.00$238,000.00$410,000.00
Intangible Assets$16.86 m$14.21 m$36.22 m
Investments000
Total Fixed Assets$17.54 m$14.45 m$36.63 m
Stocks$3.20 m$1.76 m$2.21 m
Debtors$10.60 m$3.99 m$3.95 m
Cash & Equivalents$13.95 m$3.40 m$16.34 m
Other Assets000
Total Assets$48.80 m$26.62 m$59.91 m
Liabilities202320222021
Creditors within 1 year$13.73 m$12.83 m$4.56 m
Creditors after 1 year$20.03 m$7.25 m0
Other Liabilities000
Total Liabilities$33.77 m$20.07 m$4.56 m
Net assets$15.03 m$6.54 m$55.35 m
Equity202320222021
Called up share capital$15.01 m$5.37 m$4.57 m
Share Premium$198.76 m$169.48 m$167.42 m
Profit / Loss-$32.38 m-$49.34 m-$26.87 m
Other Equity$15.03 m$6.54 m$55.35 m
Preference & Minorities000
Total Capital Employed$15.03 m$6.54 m$55.35 m
Ratios202320222021
Debt Ratio$0.57$0.530
Debt-to-Equity$1.33$1.110
Assets / Equity86.434486.434486.4344
Cash / Equity14.970414.970414.9704
EPS-$0.05-$0.15-$0.13
Cash Flow202320222021
Cash from operating activities-$37.13 m-$22.59 m-$24.65 m
Cashflow before financing$12.53 m-$14.06 m$12.75 m
Increase in Cash$10.10 m-$11.81 m$9.99 m
Income202320222021
Turnover$13.09 m$5.50 m$2.05 m
Cost of sales$9.06 m$3.04 m$1.32 m
Gross Profit$4.03 m$2.46 m$727,454.31
Operating Profit-$31.33 m-$49.75 m-$27.39 m
Pre-Tax profit-$32.38 m-$49.34 m-$26.87 m

Shield Therapeutics PLC Company Background

SectorHealthcare
ActivitiesShield Therapeutics PLC is a commercial stage specialty pharmaceutical company focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals that address areas of high unmet medical need. The company's operating segments are based on key products including PT20 and Feraccru, involves development and commercialisation of the Group's main Feraccru product, and PT20 is used in treating hyperphosphatemia, which is in its last stage of completion. The company generates maximum revenue from the Feraccru segment.
Latest Interim Date4 Sep 2024
Latest Fiscal Year End Date30 Apr 2024

Shield Therapeutics PLC Directors

AppointedNamePosition
2024-05-10Mr. Hans Peter HaslerNon-Executive Director,Chairman
2018-06-27Dr. Andrew John William HeathNon-Executive Director,Chairman
2020-06-18Mr. James Michael KarisNon-Executive Director,Chairman
2022-07-01Mr. Timothy William WattsExecutive Director
2024-05-10Ms. Maria Fabiana Lacerca-AllenNon-Executive Director
2017-09-14Ms. Joanne Elizabeth EstellExecutive Director,Chief Financial Officer
2024-07-24Mr. Gregory Paul MadisonExecutive Director,Group Chief Executive Officer
2024-05-10Mr. Peter Hermann William Llewellyn-DaviesNon-Executive Director
2017-05-04Mr. Richard Crispin Morgan JonesExecutive Director,Chief Financial Officer and Company Secretary
2020-04-22Mr. Carl Andrew SterrittExecutive Director,Chief Executive Officer
2024-05-10Dr. Christian SchweigerNon-Executive Director
2024-05-10Mr. Karl Anders LundstromExecutive Director,Chief Executive Officer (Interim)

Shield Therapeutics PLC Contact Details

Company NameShield Therapeutics PLC
AddressNorthern Design Centre Studio 6, 3rd Floor, Baltic Business Quarter, Newcastle, NE8 3DF
Telephone+44 1915118500
Websitehttps://www.shieldtherapeutics.com

Shield Therapeutics PLC Advisors

StockbrokerPeel Hunt LLP
Phone+44 2074188900
Remuneration ConsultantDeloitte LLP
Phone+44 2079363000
Fax+44 2075831198
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
SolicitorStephenson Harwood
Phone+44 2073294422
Fax+44 2073297100
StockbrokerLiberum Capital Limited
Phone+44 2031002000
Fax+44 2031002299
RegistrarCapita Asset Services
Phone+44 8716640300
Fax+44 2086392342
Nominated AdviserLiberum Capital Limited
Phone+44 2031002000
Fax+44 2031002299